Move from Resilience Conceptualization to Resilience Enhancement

This chapter provides an analysis of various resilience definitions and depicts the differences in definition between engineering, ecological and socio-ecological resilience in an easy-to-understand graphic representation. It also articulates commons and differences between conventional flood risk management and resilience-based flood management and presents a mathematical formulation to facilitate resilience discussion. Furthermore, it highlights some studies and initiatives towards the operationalization of the resilience concept in flood disaster management practice. The most important message this chapter is intended to deliver is that resilience is not just about bouncing back. Indeed, it should be enhanced to bounce forward

NetSecCC: A scalable and fault-tolerant architecture for cloud computing security

How to ensure network security for modern virtual machine based cloud computing platforms is still an open question. This question becomes more important and urgent to solve, as the fast development of cloud computing in recent years. Though there are many existing solutions, they either provide incomplete protection or neglect important intrinsic characteristics in cloud computing. In this paper, we introduce a novel network security architecture for cloud computing (NetSecCC) considering characteristics of cloud computing. Specifically, it 1) provides protection to both external and interne traffics in cloud computing, 2) attains flexible scalability with respect to virtual middlebox load, and 3) achieves fault-tolerant among virtual middlebox failure. Experiments and simulations on our proof-of-concept prototype of NetSecCC validate that NetSecCC is an effective architecture with minimal performance overhead, and that it can be applied to extensive practical promotion in cloud computing

Customized Network Security for Cloud Service

Modern cloud computing platforms based on virtual machine monitors (VMMs) host a variety of complex businesses which present many network security vulnerabilities. In order to protect network security for these businesses in cloud computing, nowadays, a number of middleboxes are deployed at front-end of cloud computing or parts of middleboxes are deployed in cloud computing. However, the former is leading to high cost and management complexity, and also lacking of network security protection between virtual machines while the latter does not effectively prevent network attacks from external traffic. To address the above-mentioned challenges, we introduce a novel customized network security for cloud service (CNS), which not only prevents attacks from external and internal traffic to ensure network security of services in cloud computing, but also affords customized network security service for cloud users. CNS is implemented by modifying the Xen hypervisor and proved by various experiments which showing the proposed solution can be directly applied to the extensive practical promotion in cloud computing

Possible Luttinger liquid behavior of edge transport in monolayer transition metal dichalcogenide crystals.

In atomically-thin two-dimensional (2D) semiconductors, the nonuniformity in current flow due to its edge states may alter and even dictate the charge transport properties of the entire device. However, the influence of the edge states on electrical transport in 2D materials has not been sufficiently explored to date. Here, we systematically quantify the edge state contribution to electrical transport in monolayer MoS2/WSe2 field-effect transistors, revealing that the charge transport at low temperature is dominated by the edge conduction with the nonlinear behavior. The metallic edge states are revealed by scanning probe microscopy, scanning Kelvin probe force microscopy and first-principle calculations. Further analyses demonstrate that the edge-state dominated nonlinear transport shows a universal power-law scaling relationship with both temperature and bias voltage, which can be well explained by the 1D Luttinger liquid theory. These findings demonstrate the Luttinger liquid behavior in 2D materials and offer important insights into designing 2D electronics

Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.

BACKGROUND: Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus (later named SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China towards the end of 2019. Large-scale spread within China and internationally led the World Health Organization to declare a Public Health Emergency of International Concern on 30th January 2020. The clinical manifestations of COVID-19 virus infection include asymptomatic infection, mild upper respiratory symptoms, severe viral pneumonia with respiratory failure, and even death. There are no antivirals of proven clinical efficacy in coronavirus infections. Remdesivir (GS-5734), a nucleoside analogue, has inhibitory effects on animal and human highly pathogenic coronaviruses, including MERS-CoV and SARS-CoV, in in vitro and in vivo experiments. It is also inhibitory against the COVID-19 virus in vitro. The aim of this study is to assess the efficacy and safety of remdesivir in adult patients with severe COVID-19. METHODS: The protocol is prepared in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. This is a phase 3, randomized, double-blind, placebo-controlled, multicentre trial. Adults (≥ 18 years) with laboratory-confirmed COVID-19 virus infection, severe pneumonia signs or symptoms, and radiologically confirmed severe pneumonia are randomly assigned in a 2:1 ratio to intravenously administered remdesivir or placebo for 10 days. The primary endpoint is time to clinical improvement (censored at day 28), defined as the time (in days) from randomization of study treatment (remdesivir or placebo) until a decline of two categories on a six-category ordinal scale of clinical status (1 = discharged; 6 = death) or live discharge from hospital. One interim analysis for efficacy and futility will be conducted once half of the total number of events required has been observed. DISCUSSION: This is the first randomized, placebo-controlled trial in COVID-19. Enrolment began in sites in Wuhan, Hubei Province, China on 6th February 2020. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04257656. Registered on 6 February 2020